Answers are grounded in this paper and cite their sources.
Prostate cancer is one of the most common malignant tumors in men. Although traditional endocrine treatments such as androgen deprivation therapy are effective in the early stage, the emergence of castration-resistant prostate cancer (CRPC) has posed a severe challenge to clinical practice. Studies have shown that prostate cancer has a unique lipid metabolism dependence, and ferroptosis, as a novel type of programmed cell death, is closely related to the lipid metabolism state of tumors, providing a new research perspective for breaking through the resistance dilemma. This article focuses on the role of the AR-SREBP1-FASN axis in the lipid metabolism reorganization and ferroptosis regulation of prostate cancer, analyzes the molecular mechanism by which androgen receptor regulates SREBP1 through transcription and activates FASN to mediate de novo synthesis of fatty acids and triglycerides, discusses the pathological significance of this pathway, and summarizes the synergistic treatment strategy of second-generation anti-androgen drugs combined with ferroptosis inducers and their potential value in reversing resistance. The analysis indicates that targeting the AR-SREBP1-FASN axis to break the lipid metabolism defense barrier is expected to provide a new therapeutic breakthrough for CRPC patients. However, the dynamic changes characteristics of this pathway in different disease stages of the human body are still unclear, and the clinical translation of specific small molecule inhibitors targeting SREBP1 or FASN still faces many obstacles, which are the directions for future research.
No takes yet. Share an insight, caveat, or question.
Yuli Zhang (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: